SKP2 and chronic myelogenous leukemia, BCR-ABL1 positive: Based on this newly identified USP10-SKP2-Bcr-Abl pathway in leukemogenesis, inhibition of USP10 is expected to be efficacious in treating CML and this study has further provided strong in vitro and in vivo evidence to support this proposition.